Welcome to our dedicated page for NuVasive news (Ticker: NUVA), a resource for investors and traders seeking the latest updates and insights on NuVasive stock.
NuVasive, Inc. (NASDAQ: NUVA) is a leader in spine technology innovation, dedicated to transforming spine surgery with minimally disruptive, procedurally integrated solutions. Headquartered in San Diego, NuVasive aims to advance surgical care and improve patient outcomes through its extensive product portfolio and global reach.
The company’s core offerings include surgical access instruments, spinal implants, fixation systems, biologics, and software for surgical planning. NuVasive also provides navigation and imaging solutions, magnetically adjustable implant systems for both spine and orthopedics, and intraoperative neuromonitoring technology and services. With an emphasis on speed of innovation, NuVasive continually develops new products to meet the evolving needs of spine surgeons, hospitals, and patients.
NuVasive has shown robust financial performance, with over $1 billion in net sales and operations in more than 50 countries. The company's recent achievements include a 2.4% increase in total net sales for the second quarter of 2023, reaching $317.8 million. This growth is driven by the adoption of new products and higher procedural volumes in the U.S.
The company is on the path to combining with Globus Medical, which is anticipated to drive further value creation for shareholders and expand its impact on improving patient lives globally. This merger is expected to enhance NuVasive's ability to deliver innovative and clinically proven outcomes.
NuVasive also emphasizes corporate social responsibility through initiatives like the NuVasive Spine Foundation®, which provides life-changing spinal surgery to disadvantaged communities, and other patient-to-patient support programs.
For more information, visit www.nuvasive.com.
NuVasive, Inc. (NASDAQ: NUVA), a leader in spine technology, announced that CFO Matt Harbaugh will speak at the Canaccord Genuity 42nd Annual Growth Conference in Boston on August 11, 2022, at 1:30 p.m. ET. A live webcast of the presentation will be available on the company's Investor Relations page, with a replay accessible for 30 days post-event. NuVasive focuses on minimally invasive surgical solutions, boasting over $1 billion in net sales and operating in more than 50 countries, catering to surgeons and hospitals.
NuVasive (NASDAQ: NUVA) announced a study in the Journal of Neurosurgery: Spine, validating the clinical and economic benefits of its synthetic solutions for lateral lumbar fusions. Conducted with 90 patients, the research showed a high effective fusion rate of 97.8% at 12 months using synthetic biologics and porous titanium implants. Attrax Putty and Modulus XLIF are highlighted as cost-effective alternatives to premium-priced biologics, promising significant cost savings for hospitals. This underscores NuVasive's commitment to innovative spine surgery solutions that improve patient outcomes and reduce costs.
On July 18, 2022, NuVasive (NASDAQ: NUVA) announced it will release its second quarter financial results on August 3, 2022, post-market. A conference call to discuss the results will take place at 4:30 PM ET, accessible via specific dial-in numbers or via a live webcast on their Investor Relations page. NuVasive, a leader in spine technology, boasts over $1 billion in net sales, offering innovative surgical solutions across more than 50 countries. For detailed information, visit www.nuvasive.com.
NuVasive (NASDAQ: NUVA) has announced the opening of its Singapore Experience Center, aimed at enhancing surgeon training and education in the Asia-Pacific region. This initiative supports the company's goal of global expansion and commitment to less-invasive spine surgery technologies. The center will provide educational resources, including a dedicated Pulse demonstration site and advanced training rooms. Chris Barry, CEO, emphasized that this investment is crucial for scaling their operations in international markets while promoting effective surgical practices.
NuVasive (NASDAQ: NUVA) reported a strong first quarter of 2022, with net sales reaching $290.8 million, reflecting a 7.2% year-over-year increase. The company saw a 9.1% rise in constant currency, driven by higher procedure volumes in the U.S. and robust international performance. GAAP diluted earnings per share improved to $0.35 compared to a loss of ($0.15) in the prior year. NuVasive updated its 2022 guidance, raising the lower end of its net sales growth forecast to 6.0%-8.0%.
Blue Spark Technologies Inc. has appointed John DeFord, Ph.D., to its board of directors, effective April 13, 2022, increasing the board size to five members. Dr. DeFord, with over 30 years in medical device leadership, aims to enhance the company’s TempTraq® platform, a remote patient monitoring solution. His extensive experience includes roles at Becton, Dickinson and Company and Cook Incorporated. The company is enthusiastic about Dr. DeFord's contributions as it seeks to establish TempTraq® as the new standard in remote monitoring.
NuVasive, Inc. (NASDAQ: NUVA) announced a significant achievement with over 100 peer-reviewed publications on its Precice® System, which addresses limb lengthening and reconstruction. Introduced in 2011, the Precice System allows non-invasive limb lengthening and has been utilized in around 15,000 procedures across 45 countries. The technology is recognized for its benefits in reducing pain and complications in patients.
The press release highlights the collaboration between global researchers, emphasizing the adoption of Precice as a standard of care in modern orthopedic practices.
NuVasive (NASDAQ: NUVA) announced the publication of peer-reviewed results from its two-level FDA Investigational Device Exemption study of the Simplify® Cervical Disc. The study, published in the Journal of Neurosurgery: Spine, highlights the disc's superior success rate compared to anterior cervical discectomy and fusion (ACDF) at the 24-month follow-up. Key findings indicate improved disability scores, reduced rates of subsequent surgeries, and better overall outcomes for patients using the Simplify Disc. This evidence supports its position as the leading technology in cervical total disc replacement.
NuVasive, Inc. (NASDAQ: NUVA) announced the upcoming release of its first quarter 2022 financial results on May 4, 2022, after market close. A conference call to discuss the results will follow at 4:30 p.m. ET. Interested parties can access the call via dial-in or webcast. NuVasive specializes in spine technology, offering minimally disruptive surgical solutions and generating over $1 billion in net sales across more than 50 countries. However, the company cautions that its forward-looking statements may involve risks and uncertainties affecting future performance.
NuVasive, Inc. (NASDAQ: NUVA) reported financial results for Q4 and full year 2021, showing net sales of $302.1 million in Q4, up 3.5%, and net sales of $1.139 billion for 2021, an 8.4% increase. However, the company faced significant challenges, with a GAAP net loss of $36.7 million in Q4 and $64.1 million for the year. Non-GAAP diluted EPS was $0.40 for Q4 and $1.68 for 2021. Looking forward, NuVasive expects net sales growth of 5.0%-8.0% in 2022, with guidance for diluted EPS of $0.71-$1.01.
FAQ
What is the market cap of NuVasive (NUVA)?
What does NuVasive, Inc. specialize in?
Where is NuVasive headquartered?
What are some of NuVasive's core products?
How did NuVasive perform in the second quarter of 2023?
Is NuVasive involved in any mergers or acquisitions?
How does NuVasive contribute to social responsibility?
What is the mission of NuVasive, Inc.?
In how many countries does NuVasive operate?
What recent financial milestone has NuVasive achieved?
Where can I find more information about NuVasive?
